- Home
- AFYA vs KNSA Comparison
AFYA vs KNSA Comparison
Compare AFYA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFYA
- KNSA
- Stock Information
- Founded
- AFYA 1999
- KNSA 2015
- Country
- AFYA Brazil
- KNSA United Kingdom
- Employees
- AFYA N/A
- KNSA N/A
- Industry
- AFYA Other Consumer Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- AFYA Real Estate
- KNSA Health Care
- Exchange
- AFYA Nasdaq
- KNSA Nasdaq
- Market Cap
- AFYA 1.6B
- KNSA 1.7B
- IPO Year
- AFYA 2019
- KNSA 2018
- Fundamental
- Price
- AFYA $16.26
- KNSA $21.09
- Analyst Decision
- AFYA Hold
- KNSA Strong Buy
- Analyst Count
- AFYA 4
- KNSA 5
- Target Price
- AFYA $21.13
- KNSA $36.60
- AVG Volume (30 Days)
- AFYA 120.1K
- KNSA 365.7K
- Earning Date
- AFYA 11-13-2024
- KNSA 10-29-2024
- Dividend Yield
- AFYA N/A
- KNSA N/A
- EPS Growth
- AFYA 61.94
- KNSA N/A
- EPS
- AFYA 1.17
- KNSA N/A
- Revenue
- AFYA $584,951,886.00
- KNSA $384,098,000.00
- Revenue This Year
- AFYA $19.06
- KNSA $60.05
- Revenue Next Year
- AFYA $11.30
- KNSA $36.32
- P/E Ratio
- AFYA $13.98
- KNSA N/A
- Revenue Growth
- AFYA 16.67
- KNSA 54.41
- 52 Week Low
- AFYA $15.52
- KNSA $15.52
- 52 Week High
- AFYA $22.48
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- AFYA 41.44
- KNSA 34.36
- Support Level
- AFYA $15.52
- KNSA $20.41
- Resistance Level
- AFYA $16.60
- KNSA $21.55
- Average True Range (ATR)
- AFYA 0.54
- KNSA 0.87
- MACD
- AFYA -0.15
- KNSA -0.14
- Stochastic Oscillator
- AFYA 25.52
- KNSA 21.90
About AFYA Afya Limited
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medicine, other health sciences, and other undergraduate programs, Continuing Education provides specialization programs and graduate courses in medicine; and Digital Services provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine, and digital prescription, and provides access, demand and efficiency for the healthcare players.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.